0 CHECKOUT

Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015

  • ID: 3495979
  • October 2015
  • 39 pages
  • Global Markets Direct
1 of 3

Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

The report ‘Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015’, provides an overview of the Five Prime Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Five Prime Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

Five Prime Therapeutics, Inc. Snapshot

Five Prime Therapeutics, Inc. Overview

Key Information

Key Facts

Five Prime Therapeutics, Inc. - Research and Development Overview

Key Therapeutic Areas

Five Prime Therapeutics, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Five Prime Therapeutics, Inc. - Pipeline Products Glance

Five Prime Therapeutics, Inc. - Clinical Stage Pipeline Products

Phase I Products/Combination Treatment Modalities

Five Prime Therapeutics, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Five Prime Therapeutics, Inc. - Drug Profiles

FPA-008

Product Description

Mechanism of Action

R&D Progress

FP-1039

Product Description

Mechanism of Action

R&D Progress

FPA-144

Product Description

Mechanism of Action

R&D Progress

INBRX-110

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Cancer

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Solid Tumors

Product Description

Mechanism of Action

R&D Progress

Proteins for Asthma and Chronic Obstructive Pulmonary Disease

Product Description

Mechanism of Action

R&D Progress

Proteins for Central Nervous System Disorders

Product Description

Mechanism of Action

R&D Progress

Five Prime Therapeutics, Inc. - Pipeline Analysis

Five Prime Therapeutics, Inc. - Pipeline Products by Target

Five Prime Therapeutics, Inc. - Pipeline Products by Route of Administration

Five Prime Therapeutics, Inc. - Pipeline Products by Molecule Type

Five Prime Therapeutics, Inc. - Pipeline Products by Mechanism of Action

Five Prime Therapeutics, Inc. - Recent Pipeline Updates

Five Prime Therapeutics, Inc. - Dormant Projects

Five Prime Therapeutics, Inc. - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Five Prime Therapeutics, Inc., Key Information

Five Prime Therapeutics, Inc., Key Facts

Five Prime Therapeutics, Inc. - Pipeline by Indication, 2015

Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2015

Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015

Five Prime Therapeutics, Inc. - Partnered Products in Pipeline, 2015

Five Prime Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015

Five Prime Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2015

Five Prime Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015

Five Prime Therapeutics, Inc. - Phase I, 2015

Five Prime Therapeutics, Inc. - Preclinical, 2015

Five Prime Therapeutics, Inc. - Discovery, 2015

Five Prime Therapeutics, Inc. - Pipeline by Target, 2015

Five Prime Therapeutics, Inc. - Pipeline by Route of Administration, 2015

Five Prime Therapeutics, Inc. - Pipeline by Molecule Type, 2015

Five Prime Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015

Five Prime Therapeutics, Inc. - Recent Pipeline Updates, 2015

Five Prime Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

Five Prime Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015

Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2015

Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015

Five Prime Therapeutics, Inc. - Partnered Products in Pipeline, 2015

Five Prime Therapeutics, Inc. - Pipeline by Top 10 Target, 2015

Five Prime Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015

Five Prime Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.